Open Payments

University Of Chicago Medical Center

Type
Non-covered entity
Where
CHICAGO, IL
Received
$9,220,958 in 752 records, 2019 to 2025 ($0 general, $9,220,958 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025Research payment164$1,618,396
2024Research payment95$1,155,044
2023Research payment122$986,453
2022Research payment163$1,218,604
2021Research payment116$2,632,796
2020Research payment52$1,055,401
2019Research payment40$554,260

By company

CompanyRecordsAmountYears
SEAGEN INC.365$3,178,6702019–2023
Amgen Inc.12$2,225,2872019–2022
Merck Sharp & Dohme LLC26$1,992,4662022–2025
Boston Scientific Corporation54$390,7352019–2024
Novartis Pharmaceuticals Corporation20$296,0832021–2025
E.R. Squibb & Sons, L.L.C.12$266,6372020–2025
Adaptive Biotechnologies Corporation89$159,6002024–2025
PFIZER INC.16$146,2792022–2024
Epizyme, Inc.82$106,7052023–2025
Deciphera Pharmaceuticals Inc.1$106,6662020
PUMA BIOTECHNOLOGY, INC.3$83,5122025
ABBVIE INC.5$57,2722023–2024
Syndax Pharmaceuticals, Inc.21$51,3782025
Iovance Biotherapeutics, Inc.1$48,4422025
TAIHO ONCOLOGY, INC.17$41,5852022–2024
Celgene Corporation1$36,1252020
Philips North America LLC4$29,2002019
CSL Behring3$2,9482025
EMD Serono, Inc.18$1,1862020–2022
UCB SA1$1592021
GUERBET LLC1$132022

By nature of payment

NatureRecordsAmount
Research payment752$9,220,958

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31Merck Sharp & Dohme LLC$529,861Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan M2025
2025-12-31Merck Sharp & Dohme LLC$135,469Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAn Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatm2025
2025-12-31Merck Sharp & Dohme LLC$94,949Research paymentIn-kind items and services Drug, ONCOLOGYMK-5684-003# A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in2025
2025-12-31Merck Sharp & Dohme LLC$45,333Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan M2025
2025-12-31Merck Sharp & Dohme LLC$34,097Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in P2025
2025-12-31Merck Sharp & Dohme LLC$30,157Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV With an2025
2025-12-31Merck Sharp & Dohme LLC$21,745Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in P2025
2025-12-31Merck Sharp & Dohme LLC$16,755Research paymentIn-kind items and servicesDEXAMETHASONE Drug, ENDOCRINOLOGYA Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of P2025
2025-12-29PUMA BIOTECHNOLOGY, INC.$21,385Research paymentCash or cash equivalentALI-12012025
2025-12-26Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-12-24Syndax Pharmaceuticals, Inc.$7,258Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-12-24Syndax Pharmaceuticals, Inc.$1,516Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-12-24Syndax Pharmaceuticals, Inc.$1,516Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-12-24Syndax Pharmaceuticals, Inc.$1,516Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-12-21Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-12-15Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-12-08Epizyme, Inc.$78Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-12-04Novartis Pharmaceuticals Corporation$3,250Research paymentCash or cash equivalentA Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroi2025
2025-12-01Epizyme, Inc.$1,544Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-12-01Epizyme, Inc.$1,466Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-12-01Epizyme, Inc.$1,466Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-12-01Epizyme, Inc.$1,311Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-12-01Epizyme, Inc.$1,311Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-12-01Epizyme, Inc.$1,311Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-12-01Epizyme, Inc.$1,182Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-12-01Epizyme, Inc.$1,182Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-12-01Epizyme, Inc.$1,182Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-12-01Epizyme, Inc.$1,182Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-12-01Epizyme, Inc.$1,182Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-12-01Epizyme, Inc.$926Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-12-01Novartis Pharmaceuticals Corporation$405Research paymentIn-kind items and servicesAn Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid T2025
2025-11-28Epizyme, Inc.$1,544Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-11-28Epizyme, Inc.$1,466Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-11-28Epizyme, Inc.$1,182Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-11-28Epizyme, Inc.$1,182Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-11-28Epizyme, Inc.$926Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-11-15Novartis Pharmaceuticals Corporation$91Research paymentIn-kind items and servicesKYMRIAH Drug, OncologyA single arm phase II trial in first line high risk HR pediatric and young adult patients with Bcell acute lymphoblastic2025
2025-11-14PUMA BIOTECHNOLOGY, INC.$8,370Research paymentCash or cash equivalentALI-12012025
2025-11-14Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-11-09Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-10-30Syndax Pharmaceuticals, Inc.$8,599Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-10-30Syndax Pharmaceuticals, Inc.$2,099Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-10-30Syndax Pharmaceuticals, Inc.$1,516Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-10-08Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-10-08CSL Behring$172Research paymentIn-kind items and servicesA Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcom2025
2025-10-07Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-10-06Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-10-03Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-10-02Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-09-25Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-09-24Epizyme, Inc.$2,617Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$2,617Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$2,617Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$1,651Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$1,651Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$1,651Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$1,544Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$1,544Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Syndax Pharmaceuticals, Inc.$1,516Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-09-24Epizyme, Inc.$1,466Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$1,311Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$1,238Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$1,238Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$1,238Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$1,182Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$1,182Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$1,182Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$1,182Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$1,182Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$1,182Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$987Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$987Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$987Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$926Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$926Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$874Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$874Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$874Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$651Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$651Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-24Epizyme, Inc.$651Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-09-22CSL Behring$1,764Research paymentIn-kind items and servicesA Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcom2025
2025-09-14Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-09-10Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-09-06Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-09-02Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-08-31Merck Sharp & Dohme LLC$116,236Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma 2025
2025-08-31Merck Sharp & Dohme LLC$33,210Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Study of Pembrolizumab in combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel followed by Pembrol2025
2025-08-29Epizyme, Inc.$78Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-08-21Syndax Pharmaceuticals, Inc.$8,599Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-08-21Syndax Pharmaceuticals, Inc.$7,258Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-08-21Syndax Pharmaceuticals, Inc.$2,099Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-08-21Syndax Pharmaceuticals, Inc.$1,516Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-08-21Syndax Pharmaceuticals, Inc.$302Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-08-21Syndax Pharmaceuticals, Inc.$302Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-08-21Syndax Pharmaceuticals, Inc.$302Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-08-21Syndax Pharmaceuticals, Inc.$302Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-08-14Adaptive Biotechnologies Corporation$1,200Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-08-13Epizyme, Inc.$78Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-07-28Epizyme, Inc.$156Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-07-08Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-06-28Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-06-20Adaptive Biotechnologies Corporation$31,200Research paymentCash or cash equivalentimmunoSEQ Device, Devices19-0339_R2025
2025-06-18Epizyme, Inc.$1,651Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-06-18Syndax Pharmaceuticals, Inc.$1,516Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-06-16Epizyme, Inc.$4,096Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-06-16Epizyme, Inc.$2,560Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-06-16Epizyme, Inc.$2,560Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-06-16Epizyme, Inc.$1,536Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-06-16Epizyme, Inc.$650Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-06-16Epizyme, Inc.$650Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-06-16Epizyme, Inc.$650Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-06-16Epizyme, Inc.$67Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-06-04Epizyme, Inc.$1,603Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-06-04Epizyme, Inc.$509Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-06-02Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-05-23Syndax Pharmaceuticals, Inc.$1,516Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-05-23Syndax Pharmaceuticals, Inc.$1,516Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-05-23Syndax Pharmaceuticals, Inc.$302Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-05-23Syndax Pharmaceuticals, Inc.$302Research paymentCash or cash equivalentREVUFORJ Drug, HEMATOLOGY-ONCOLOGYA MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL)2025
2025-05-20Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-04-30Epizyme, Inc.$2,827Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-04-30Epizyme, Inc.$2,827Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-04-30Epizyme, Inc.$1,416Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-04-30Epizyme, Inc.$1,297Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-04-30Epizyme, Inc.$1,182Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-04-30Epizyme, Inc.$1,124Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-04-29Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-04-25Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-04-21Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-04-19Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-04-18Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-04-02Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-04-01Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-03-31Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-03-28Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-03-24Epizyme, Inc.$1,064Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-03-21Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-03-20Epizyme, Inc.$1,651Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-03-20Epizyme, Inc.$1,124Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-03-14PUMA BIOTECHNOLOGY, INC.$53,757Research paymentCash or cash equivalentALI-12012025
2025-03-13Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-03-11Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-03-07Epizyme, Inc.$156Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-03-05Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-03-03Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-03-02Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-03-01Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-02-23Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-02-11CSL Behring$1,011Research paymentIn-kind items and servicesA Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evalu2025
2025-02-10Novartis Pharmaceuticals Corporation$63,844Research paymentCash or cash equivalentA Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients Wit2025
2025-02-05Epizyme, Inc.$2,827Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-02-05Epizyme, Inc.$1,297Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-02-05Epizyme, Inc.$509Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2025
2025-02-02Adaptive Biotechnologies Corporation$1,200Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-01-30Iovance Biotherapeutics, Inc.$48,442Research paymentCash or cash equivalentAmtagvi Drug, OncologyNCT053611742025
2025-01-19Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-01-17Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, Devices19-03392025
2025-01-15Novartis Pharmaceuticals Corporation$459Research paymentIn-kind items and servicesKYMRIAH Drug, OncologyA single arm phase II trial in first line high risk HR pediatric and young adult patients with Bcell acute lymphoblastic2025
2025-01-10E.R. Squibb & Sons, L.L.C.$21,500Research paymentCash or cash equivalentOPDIVO Biological, OncologyA Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plu2025
2025-01-09Novartis Pharmaceuticals Corporation$96,033Research paymentCash or cash equivalentA Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroi2025
2025-01-07E.R. Squibb & Sons, L.L.C.$11,280Research paymentCash or cash equivalentOPDIVO Biological, OncologyRandomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versu2025
2025-01-06Merck Sharp & Dohme LLC$20,000Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV With an2025
2025-01-01Novartis Pharmaceuticals Corporation$4,376Research paymentIn-kind items and servicesAn Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid T2025
2024-12-31Merck Sharp & Dohme LLC$441,684Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan M2024
2024-12-31Merck Sharp & Dohme LLC$66,420Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma 2024
2024-12-31Merck Sharp & Dohme LLC$43,411Research paymentIn-kind items and services Drug, ONCOLOGYA Phase 3 Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants2024
2024-12-31Merck Sharp & Dohme LLC$41,732Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab plus Enfortumab Vedotin EV i2024
2024-12-31Merck Sharp & Dohme LLC$29,496Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV in Comb2024
2024-12-31Merck Sharp & Dohme LLC$25,614Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab in P2024
2024-12-31Merck Sharp & Dohme LLC$14,182Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYA Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan M2024
2024-12-16Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, ONCOLOGYA Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple 2024
2024-12-14Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, ONCOLOGYA Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple 2024
2024-12-03Boston Scientific Corporation$4,303Research paymentCash or cash equivalentPrecision Device, Precision_NMDParesthesia-Free Fast-Acting Subperception Study2024
2024-12-02Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, ONCOLOGYA Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple 2024
2024-11-30Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, ONCOLOGYA Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple 2024
2024-11-05Boston Scientific Corporation$2,799Research paymentCash or cash equivalentPrecision Device, Precision_NMDParesthesia-Free Fast-Acting Subperception Study2024
2024-10-17Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, ONCOLOGYA Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple 2024
2024-10-08Boston Scientific Corporation$7,754Research paymentCash or cash equivalentPrecision Device, Precision_NMDParesthesia-Free Fast-Acting Subperception Study2024
2024-10-02PFIZER INC.$2,388Research paymentCash or cash equivalentPADCEV Biological, OncologyA DOSEESCALATION AND DOSEEXPANSION STUDY OF ENFORTUMAB VEDOTIN ASG22CE IN COMBINATION WITH PEMBROLIZUMAB ANDOR CHEMOTHER2024
2024-09-26Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, ONCOLOGYA Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple 2024
2024-09-15Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, ONCOLOGYA Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple 2024
2024-09-10Boston Scientific Corporation$3,900Research paymentCash or cash equivalentPrecision Device, Precision_NMDParesthesia-Free Fast-Acting Subperception Study2024
2024-08-28Epizyme, Inc.$1,525Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2024
2024-08-28Epizyme, Inc.$1,466Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2024
2024-08-28Epizyme, Inc.$1,182Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2024
2024-08-26Adaptive Biotechnologies Corporation$1,200Research paymentCash or cash equivalentclonoSEQ Device, ONCOLOGYA Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple 2024
2024-08-24Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, ONCOLOGYA Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple 2024
2024-08-19Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, ONCOLOGYA Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple 2024
2024-08-16Epizyme, Inc.$78Research paymentCash or cash equivalentTazverik Drug, OncologySymphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat 2024
2024-08-13Boston Scientific Corporation$4,879Research paymentCash or cash equivalentPrecision Device, Precision_NMDParesthesia-Free Fast-Acting Subperception Study2024
2024-08-12Adaptive Biotechnologies Corporation$1,200Research paymentCash or cash equivalentclonoSEQ Device, ONCOLOGYA Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple 2024
2024-08-07PFIZER INC.$4,768Research paymentCash or cash equivalentPADCEV Biological, OncologyA DOSEESCALATION AND DOSEEXPANSION STUDY OF ENFORTUMAB VEDOTIN ASG22CE IN COMBINATION WITH PEMBROLIZUMAB ANDOR CHEMOTHER2024
2024-07-23Adaptive Biotechnologies Corporation$19,200Research paymentCash or cash equivalentimmunoSEQ Device, ONCOLOGYA Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple 2024
2024-07-19Adaptive Biotechnologies Corporation$35,400Research paymentCash or cash equivalentimmunoSEQ Device, ONCOLOGYOpen-label, Single-arm, Phase 2 Study of Initial Treatment With Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalido2024
2024-07-10PFIZER INC.$5,500Research paymentCash or cash equivalentPADCEV Biological, OncologyA DOSEESCALATION AND DOSEEXPANSION STUDY OF ENFORTUMAB VEDOTIN ASG22CE IN COMBINATION WITH PEMBROLIZUMAB ANDOR CHEMOTHER2024
2024-07-05Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, ONCOLOGYA Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple 2024
2024-07-03Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, ONCOLOGYA Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple 2024
2024-07-02Adaptive Biotechnologies Corporation$600Research paymentCash or cash equivalentclonoSEQ Device, ONCOLOGYA Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple 2024
2024-06-24ABBVIE INC.$9,250Research paymentIn-kind items and servicesVENCLEXTA Drug, ONCOLOGYPhase 1b Study of Venetoclax in Combination with Intensive Induction and Consolidation Chemotherapy in Treatment Naive S2024

The latest 200 records of 752.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Cook CountyChicago city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Chicago, IL, county Cook County, IL, state Illinois; placed by its city name.

MeasurePlace (city or town)
Chicago, IL
County
Cook County, IL
State
Illinois
Population B010032,711,2265,182,09012,694,798
Population, 2020 census P12,746,3885,275,54112,812,508
Median age B0100235.838.039.0
Under 18 B0100119.4%21.1%21.8%
65 and over B0100113.8%16.0%17.0%
Households B110011,160,2052,100,2305,036,449
Foreign born B0500220.9%21.7%14.7%
Median household income B19013$77,902$83,498$83,390
Median family income B19113$95,774$104,836$106,018
Per capita income B19301$50,086$49,329$46,406
Poverty rate B1700116.8%13.5%11.8%
Unemployment rate B230258.0%7.0%5.8%
Civilian labor force B230251,517,3302,792,8886,652,134
Mean commute (minutes) B0801333.131.527.8
Bachelor's degree or higher B1500344.3%42.7%37.8%
Housing units B250011,277,0542,276,4935,457,452
Owner-occupied B2500346.0%57.7%67.1%
Renters B2500354.0%42.3%32.9%
Median home value B25077$334,100$324,500$263,300
Median gross rent B25064$1,440$1,435$1,274
White, not Hispanic B0300232.1%40.1%58.1%
Black B0300227.4%21.8%13.3%
Hispanic or Latino B0300229.7%26.8%18.8%
Asian B030027.2%7.9%5.9%
American Indian and Alaska Native B030020.1%0.1%0.1%

Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); Unemployment rate: 5.7% in Sep 2016 to 4.6% in Sep 2026; low 3.6%, high 18.3% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Chicago, IL.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.